Proteins that form clumps occur in many difficult-to-treat diseases, such as ALS, Alzheimer’s, and Parkinson’s.
Abcam agrees to $5.7B sale to Danaher amid founder’s push for a board seat
Danaher will buy Abcam, a research tools supplier relied upon by many biopharmas, for an enterprise value of about $5.7 billion, the companies announced Monday